search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patients


- candidate number24165
- NTR NumberNTR5732
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR31-mrt-2016
- Secondary IDsMEC-2016-081 
- Public TitleQuantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patients
- Scientific TitleQuantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patients
- ACRONYMCIRCUS Study
- hypothesisWith the quantification of circulating tumor DNA treatment response assessment will improve in metastatic prostate cancer patients.
- Healt Condition(s) or Problem(s) studiedProstatic neoplasms, Metastasis
- Inclusion criteria- Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Measurable metastatic lesion(s) according to PCWG2 and/or RECIST 1.1 criteria
- Intention to start (new) line of systemic treatment
- Written informed consent
- Willingness and capacity to follow the protocol specified visits for blood sampling for the total duration of the study.
- Age ≥ 18 years.
- WHO performance status ≤2.
- Concurrent participation in CPCT-02 study
- Exclusion criteriaNA
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- group[default]
- Type[default]
- Studytypeobservational
- planned startdate 8-apr-2016
- planned closingdate1-feb-2020
- Target number of participants95
- InterventionsRepeated blood drawns and urine collection
- Primary outcomeThe rate of mPC patients with quantifiable ctDNA taken pre-treatment.
- Secondary outcome- The percentage of blood samples with sufficient ctDNA.
- The interval between detected ctDNA and PSA response during treatment.
- The correlation between ctDNA response and progression-free survival.
- TimepointsEnrolment should be completed within 3 years.
- Trial web site
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES L.F. van Dessel
- CONTACT for SCIENTIFIC QUERIES Martijn P. Lolkema
- Sponsor/Initiator Erasmus Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Erasmus Medical Center
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD31-mrt-2016 - 22-mei-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl